Safety and Efficacy of Melflufen and Dexamethasone in Relapsed and/or Relapsed-Refractory Multiple Myeloma Patients
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT01897714 |
Recruitment Status
:
Active, not recruiting
First Posted
: July 12, 2013
Last Update Posted
: March 21, 2018
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Relapsed and/or Relapsed-refractory Multiple Myeloma | Drug: Melflufen Drug: Dexamethasone | Phase 1 Phase 2 |
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 75 participants |
Intervention Model: | Single Group Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Treatment |
Official Title: | An Open-Label Phase I/IIa Study of the Safety and Efficacy of Melphalan-flufenamide (Melflufen) and Dexamethasone Combination for Patients With Relapsed and/or Relapsed-Refractory Multiple Myeloma |
Study Start Date : | July 2013 |
Actual Primary Completion Date : | December 2017 |
Estimated Study Completion Date : | October 2019 |

Arm | Intervention/treatment |
---|---|
Experimental: Melflufen and dexamethasone in combination
Intravenous infusion of melflufen Day 1 of 21 day cycles, in combination with 40 mg dexamethasone (oral or i.v.) day 1, 8 and 15 of the 21 day cycles.
|
Drug: Melflufen Drug: Dexamethasone |
- The primary objective of the Phase I portion of the study is to determine the Maximum Tolerated Dose (MTD) of the combination of melflufen and dexamethasone in patients with relapsed and/or relapsed-refractory Multiple Myeloma. [ Time Frame: 21 days ]
- The primary objective of the Phase IIa part is to evaluate the objective response rate to the combination of melflufen and dexamethasone at the MTD determined in the Phase I part [ Time Frame: Up to 24 weeks ]

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Senior) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Male or female, age 18 years or older
- Patient has a diagnosis of multiple myeloma with documented relapsed and/or relapsed-refractory disease
-
Patient has measurable disease defined as any of the following:
- Serum monoclonal protein ≥ 0.5 g/dL by protein electrophoresis
- ≥200 mg of monoclonal protein in the urine on 24-hour electrophoresis
- Serum immunoglobulin free light chain ≥10 mg/dL AND abnormal serum immunoglobulin kappa to lambda free light chain ratio
- If no monoclonal protein is detected, then ≥ 30% monoclonal bone marrow plasma cells
- Patient has had at least 2 or more prior lines of therapy including lenalidomide and bortezomib and has demonstrated disease progression on or within 60 days of completion of the last therapy
- Life expectancy of ≥6 months
- Patient has an ECOG performance status ≤ 2 (Patients with lower performance status based solely on bone pain secondary to multiple myeloma will be eligible)
- Females of childbearing potential must have a negative serum or urine pregnancy test prior to patient registration
- Female patients of child bearing potential and non-vasectomized male patients agree to practice appropriate methods of birth control
- Ability to understand the purpose and risks of the study and provide signed and dated informed consent and authorization to use protected health information
- The patient has, or accepts to have, an acceptable infusion device for infusion of melflufen
- 12 lead ECG with QtcF interval ≤ 470 msec
-
The following laboratory results must be met within 21 days of patient registration:
- Absolute neutrophil count ≥ 1,000 cells/dL (1.0 x 109/L)
- Platelet count ≥ 75,000 cells/dL (75 x 109/L)
- Hemoglobin ≥ 8.0 g/dL
- Total Bilirubin ≤ 1.5 x upper limit of normal
- Renal function: Estimated creatinine clearance ≥ 45 ml/min or serum creatinine ≤ 2.5 mg/dL
- AST (SGOT) and ALT (SGPT) ≤ 3.0 x ULN
Exclusion Criteria:
- Patient has evidence of mucosal or internal bleeding and/or is platelet transfusion refractory
- Any medical conditions that, in the Investigator's opinion, would impose excessive risk to the patient or would adversely affect his/her participation in this study
- Known active infection requiring parenteral or oral anti-infective treatment
- Other malignancy within the past 3 years with the exception of adequately treated basal cell carcinoma, squamous cell skin cancer, carcinoma in-situ of the cervix
- Other ongoing anti-myeloma therapy. Patients may be receiving concomitant therapy with bisphosphonates and low dose corticosteroids for symptom management and comorbid conditions. Doses of corticosteroid should be stable for at least 7 days prior to patient registration.
- Pregnant or breast-feeding females
- Serious psychiatric illness, active alcoholism, or drug addiction that may hinder or confuse follow-up evaluation
- Known HIV or hepatitis B or C viral infection
- Patient has concurrent symptomatic amyloidosis or plasma cell leukemia
- POEMS syndrome
- Previous cytotoxic therapies, including cytotoxic investigational agents, for multiple myeloma within 3 weeks (6 weeks for nitrosoureas) prior to start of study treatment. Biologic, novel therapy (including investigational agents in this class) or corticosteroids within 2 weeks prior to patient registration. Patient has side effects of the previous therapy > grade 1 or previous baseline.
- Prior peripheral stem cell transplant within 12 weeks of patient registration
- Radiotherapy within 21 days prior to Cycle 1 Day 1. However, if the radiation portal covered ≤ 5% of the bone marrow reserve, the patient may be enrolled irrespective of the end date of radiotherapy
- Known intolerance to steroid therapy

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01897714
United States, Massachusetts | |
Dana Farber Cancer Institute | |
Boston, Massachusetts, United States, 02215 | |
United States, Michigan | |
Karmanos Cancer Center | |
Detroit, Michigan, United States, 48201 | |
United States, North Carolina | |
Universtity of North Carolina | |
Chapel Hill, North Carolina, United States, 27514 | |
Denmark | |
Vejle Hospital | |
Vejle, Denmark | |
Italy | |
Turin Hospital Myeloma Unit | |
Turin, Italy | |
Netherlands | |
Erasmus University Medical Center | |
Rotterdam, Netherlands | |
Sweden | |
Sahlgrenska Hospital | |
Gothenburg, Sweden |
Study Director: | Paul G Richardson, MD | Dana Farber Cancer Institute, Boston MA, USA | |
Study Director: | Johan Harmenberg, MD | Oncopeptides AB, Stockholm, Sweden |
Responsible Party: | Oncopeptides AB |
ClinicalTrials.gov Identifier: | NCT01897714 History of Changes |
Other Study ID Numbers: |
O-M1-12 |
First Posted: | July 12, 2013 Key Record Dates |
Last Update Posted: | March 21, 2018 |
Last Verified: | March 2018 |
Additional relevant MeSH terms:
Multiple Myeloma Neoplasms, Plasma Cell Neoplasms by Histologic Type Neoplasms Hemostatic Disorders Vascular Diseases Cardiovascular Diseases Paraproteinemias Blood Protein Disorders Hematologic Diseases Hemorrhagic Disorders Lymphoproliferative Disorders Immunoproliferative Disorders Immune System Diseases Dexamethasone acetate |
Dexamethasone BB 1101 Anti-Inflammatory Agents Antiemetics Autonomic Agents Peripheral Nervous System Agents Physiological Effects of Drugs Gastrointestinal Agents Glucocorticoids Hormones Hormones, Hormone Substitutes, and Hormone Antagonists Antineoplastic Agents, Hormonal Antineoplastic Agents Protease Inhibitors Enzyme Inhibitors |